论文部分内容阅读
目的 探讨E-Cad 在肺癌及淋巴转移灶中的表达及其临床意义。方法 应用免疫组织化学S-P法检测30 例正常肺组织、63 例肺癌患者原发灶及其中41 例淋巴结转移灶中E-Cad 的表达。结果 正常肺组织均显示清楚的细胞膜染色,肺癌原发灶及淋巴转移灶中E-Cad 异常表达率分别为53.97 % (34/63)和63.41 % (26/41),两者无显著性差异(P> 0.05),但均和正常肺组织有显著性差异(P< 0.001);E-Cad 异常表达率与肺癌类型无关(P> 0.05),和P-TNM 分期、病理分级及淋巴转移密切相关(P< 0.05～0.001)。结论 E-Cad 基因为一肿瘤抑制基因,E-Cad 是反映肺癌生物学行为、预测肺癌转移潜能的很有价值的指标
Objective To investigate the expression and clinical significance of E-Cad in lung cancer and lymph metastases. Methods Immunohistochemical S-P method was used to detect the expression of E-cadherin in the primary lesions and 41 metastatic lymph nodes in 30 normal lung tissues, 63 lung cancer patients. Results The normal lung tissues showed clear cell membrane staining. The abnormal expression rates of E-Cad in primary lung cancer and lymph node metastasis were 53.97 % (34/63) and 63.41 % (26/41), respectively. There was no significant difference between the two groups. (P> 0.05), but all had significant differences with normal lung tissue (P < 0.001); the abnormal expression rate of E-Cad was not associated with lung cancer type (P> 0.05), and was closely related to P-TNM stage, pathological grade, and lymph node metastasis. Correlation (P < 0.05 to 0.001). Conclusion E-Cad gene is a tumor suppressor gene. E-Cad is a valuable indicator reflecting the biological behavior of lung cancer and predicting the metastatic potential of lung cancer.